Nexera Holds Annual Meeting of Shareholders and Announces Election of Directors

All director nominees reelected and all other company proposals approved by shareholders

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 21, 2023) - Nexera Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Nexera shareholders elected all nominees listed in Nexera's management information circular dated August 9, 2023 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors and in favor of resolutions amending the company's equity incentive compensation plan.

Detailed voting results for the election of directors are set out in the table below.

Shareholders also cast 7,498,887 (99.55%) votes for and withheld 33,641 (0.45%) votes from the appointment of PricewaterhouseCoopers LLP as the company's auditors, and cast 6,567,139 (98.76%) votes for and 82,697 (1.24%) votes against the resolutions amending Nexera's equity incentive compensation plan. All proposals were therefore approved.

Final voting results on all matters voted on at the annual meeting will be filed with Canadian securities regulatory authorities at www.sedarplus.com.

About Nexera

Nexera is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Nexera's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Nexera and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.com.

Contacts

Ashok Kumar | CEO, Nexera Pharmaceuticals
Tel: +18733007637 | Email: ashok.kumar@nexerapharmaceuticals.com

Marcel Konrad | CFO, Nexera Pharmaceuticals
Tel: 312-548-3139 | Email: marcel.konrad@nexerapharmaceuticals.com

Forward-looking statements

Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Nexera cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include, but are not limited to, those set out in Nexera's materials filed with the Canadian securities regulatory authorities from time to time, including Nexera's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Nexera undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/181423

SOURCE Nexera Pharmaceuticals Inc.

Released September 21, 2023